Last update 08 May 2025

CD123 x DNA

Basic Info

Related Targets
CD123DNA

Related

2
Drugs associated with CD123 x DNA
BYON-4413
Target
CD123 x DNA
Mechanism
CD123 modulators [+1]
Active Org.
Byondis BVByondis BV
Originator Org.
Byondis BVByondis BV
Active Indication
Acute Myeloid Leukemia [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
SGN-CD123A
Target
CD123 x DNA
Mechanism
CD123 inhibitors [+1]
Active Org.-
Originator Org.
Seagen, Inc.Seagen, Inc.
Active Indication-
Inactive Indication
Refractory acute myeloid leukemia [+1]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with CD123 x DNA
NCT06359002
/ RecruitingPhase 1
A First-in-human Dose Escalation and Expansion Trial With the Antibody-drug Conjugate BYON4413 to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms.
NCT02848248
/ TerminatedPhase 1
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
100 Clinical Results associated with CD123 x DNA
Login to view more data
100 Translational Medicine associated with CD123 x DNA
Login to view more data
0 Patents (Medical) associated with CD123 x DNA
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free